down arrow

Cencora, Inc.

  • Market Cap: Large Cap
  • Industry: Retailing
  • ISIN: US03073E1055
USD
337.63
2.32 (0.69%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

334.03338.07

52 Week

223.92377.54
Valuation
Technical
Day's Volume

CASH

427.1 k

Shareholding (Mar 2025)

FII

21.96%

Held by 424 FIIs

DII

32.41%

Held by 63 DIIs

Promoter

5.37%

How big is Cencora, Inc.?

22-Jun-2025

As of Jun 18, Cencora, Inc. has a market capitalization of 81,057.12 million and net sales of 310,232.19 million with a net profit of 1,706.20 million for the latest four quarters. As of Sep 24, shareholder's funds are 645.94 million and total assets are 67,101.67 million.

As of Jun 18, Cencora, Inc. has a market capitalization of 81,057.12 million, categorizing it as a Large Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 310,232.19 million, while the sum of Net Profit for the same period is 1,706.20 million.<BR><BR>As of Sep 24, the reporting period shows Shareholder's Funds at 645.94 million and Total Assets amounting to 67,101.67 million.

Read More

What does Cencora, Inc. do?

22-Jun-2025

Cencora, Inc. is a large-cap pharmaceutical sourcing and distribution services company with recent net sales of $75.454 billion and a net profit of $717 million. Key metrics include a P/E ratio of 44.00 and a dividend yield of 40.29%.

Overview:<BR>Cencora, Inc. is a pharmaceutical sourcing and distribution services company operating in the retailing industry, categorized as a large-cap entity.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 75,454 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 717 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 81,057.12 Million (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 44.00<BR>- Dividend Yield: 40.29%<BR>- Debt Equity: 5.67<BR>- Return on Equity: 177.43%<BR>- Price to Book: 80.03<BR><BR>Contact Details:<BR>- Address: 1300 Morris Dr, CHESTERBROOK PA: 19087-5594<BR>- Tel: 1 610 7277000<BR>- Fax: 1 302 6555049

Read More

Who are in the management team of Cencora, Inc.?

22-Jun-2025

As of March 2022, the management team of Cencora, Inc. includes Steven Collis (Chairman, President, CEO), Dr. Jane Henney (Lead Independent Director), and Directors Ornella Barra, D. Mark Durcan, Richard Gochnauer, and Lon Greenberg. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Cencora, Inc. includes the following individuals:<BR><BR>- Mr. Steven Collis, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Dr. Jane Henney, who is the Lead Independent Director.<BR>- Ms. Ornella Barra, who is a Director.<BR>- Mr. D. Mark Durcan, who is an Independent Director.<BR>- Mr. Richard Gochnauer, who is also an Independent Director.<BR>- Mr. Lon Greenberg, who serves as an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Read More

Is Cencora, Inc. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Cencora, Inc. shows a mildly bullish trend overall, supported by monthly indicators and strong year-to-date performance, despite a recent weekly decline.

As of 1 August 2025, the technical trend for Cencora, Inc. has changed from sideways to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, supporting the overall positive trend. The Bollinger Bands show a sideways movement on the weekly chart but are mildly bullish on the monthly chart. The KST and Dow Theory indicate a mildly bearish stance on the weekly level but bullish on the monthly.<BR><BR>In terms of performance, Cencora has outperformed the S&P 500 year-to-date with a return of 29.45% compared to the S&P 500's 12.22%. However, over the last week, the stock has declined by 3.95%, while the S&P 500 gained 1.05%. Overall, the current stance is mildly bullish, driven by monthly indicators and strong longer-term performance.

Read More

Is Cencora, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Cencora, Inc. is fairly valued with a P/E ratio of 44, outperforming the S&P 500 with a year-to-date return of 44.51%, while its valuation metrics are more favorable compared to Boston Scientific and McKesson.

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is at a risky valuation with a P/E of 57.25.<BR><BR>Cencora's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%. This strong performance reinforces the notion that the stock is fairly valued in the current market environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROCE of 68.36%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 11.19%

 
4

Flat results in Jun 25

5

With ROCE of 47.11%, it has a expensive valuation with a 12.67 Enterprise value to Capital Employed

6

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 82,362 Million (Large Cap)

stock-summary
P/E

44.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

27.26%

stock-summary
Debt Equity

3.01

stock-summary
Return on Equity

103.76%

stock-summary
Price to Book

41.59

Revenue and Profits:
Net Sales:
80,664 Million
(Quarterly Results - Jun 2025)
Net Profit:
690 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.35%
0%
15.35%
6 Months
16.82%
0%
16.82%
1 Year
35.95%
0%
35.95%
2 Years
65.7%
0%
65.7%
3 Years
94.05%
0%
94.05%
4 Years
189.17%
0%
189.17%
5 Years
227.86%
0%
227.86%

Cencora, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Cencora, Inc. Hits New 52-Week High at $350.46, Up 45.46%

Cencora, Inc. Hits New 52-Week High at $350.46, Up 45.46%

Cencora, Inc. has achieved a new 52-week high, reflecting strong performance with a significant increase over the past year. The company, with a market capitalization of USD 82,362 million, features a high P/E ratio and a notable dividend yield, alongside impressive return on equity and a considerable debt-to-equity ratio.

Read More
Cencora, Inc. Hits New 52-Week High at $334.27, Showcasing Strong Growth

Cencora, Inc. Hits New 52-Week High at $334.27, Showcasing Strong Growth

Cencora, Inc. has achieved a new 52-week high of USD 334.27, reflecting a strong performance with a 41.84% increase over the past year. The company, with a market cap of USD 82,362 million, features a P/E ratio of 44.00 and a notable dividend yield of 27.26%.

Read More
Cencora, Inc. Hits New 52-Week High at USD 331.73

Cencora, Inc. Hits New 52-Week High at USD 331.73

Cencora, Inc. achieved a new 52-week high of USD 331.73 on October 22, 2025, reflecting a significant performance increase over the past year. With a market capitalization of USD 82,362 million, the company shows strong financial metrics, including a high return on equity and substantial dividend yield.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.19%
EBIT Growth (5y)
13.41%
EBIT to Interest (avg)
12.09
Debt to EBITDA (avg)
0.78
Net Debt to Equity (avg)
5.67
Sales to Capital Employed (avg)
43.96
Tax Ratio
25.90%
Dividend Payout Ratio
27.07%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
68.36%
ROE (avg)
353.31%
Valuation key factors
Factor
Value
P/E Ratio
44
Industry P/E
Price to Book Value
78.87
EV to EBIT
26.89
EV to EBITDA
20.00
EV to Capital Employed
12.67
EV to Sales
0.28
PEG Ratio
NA
Dividend Yield
40.88%
ROCE (Latest)
47.11%
ROE (Latest)
177.43%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 182 Schemes (40.25%)

Foreign Institutions

Held by 424 Foreign Institutions (21.96%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 8.65% vs 10.90% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 41.45% vs 1.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "80,663.50",
          "val2": "74,241.40",
          "chgp": "8.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,241.70",
          "val2": "982.30",
          "chgp": "26.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "116.90",
          "val2": "58.90",
          "chgp": "98.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-103.10",
          "val2": "-30.90",
          "chgp": "-233.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "689.70",
          "val2": "487.60",
          "chgp": "41.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.20%",
          "val2": "9.50%",
          "chgp": "0.27%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 12.12% vs 9.89% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is -12.31% vs 3.97% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "293,958.60",
          "val2": "262,173.40",
          "chgp": "12.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,151.80",
          "val2": "3,418.90",
          "chgp": "21.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "248.70",
          "val2": "275.60",
          "chgp": "-9.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-827.00",
          "val2": "-105.50",
          "chgp": "-683.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,519.30",
          "val2": "1,732.60",
          "chgp": "-12.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "10.30%",
          "val2": "9.30%",
          "chgp": "0.10%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
80,663.50
74,241.40
8.65%
Operating Profit (PBDIT) excl Other Income
1,241.70
982.30
26.41%
Interest
116.90
58.90
98.47%
Exceptional Items
-103.10
-30.90
-233.66%
Consolidate Net Profit
689.70
487.60
41.45%
Operating Profit Margin (Excl OI)
12.20%
9.50%
0.27%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 8.65% vs 10.90% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 41.45% vs 1.75% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
293,958.60
262,173.40
12.12%
Operating Profit (PBDIT) excl Other Income
4,151.80
3,418.90
21.44%
Interest
248.70
275.60
-9.76%
Exceptional Items
-827.00
-105.50
-683.89%
Consolidate Net Profit
1,519.30
1,732.60
-12.31%
Operating Profit Margin (Excl OI)
10.30%
9.30%
0.10%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2024 is 12.12% vs 9.89% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is -12.31% vs 3.97% in Sep 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cencora, Inc. stock-summary
stock-summary
Cencora, Inc.
Retailing
AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company's segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.
Company Coordinates stock-summary
Company Details
1300 Morris Dr , CHESTERBROOK PA : 19087-5594
stock-summary
Tel: 1 610 7277000
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."